START has dosed the first patient in the MOMA-313 clinical trial
The START Center for Cancer Research shared a post by MOMA Therapeutics, on LinkedIn, adding:
“We are proud to share that START has dosed the first patient in the MOMA-313 clinical trial, a Phase 1 study sponsored by MOMA Therapeutics.
Dr. Amita Patnaik, who dosed the first patient stated, ‘We are very excited to have dosed the first subject with MOMA-313 at The START Center for Cancer Research in San Antonio, Texas.
MOMA-313 is a highly novel, potent and selective small molecule inhibitor of polymerase theta, representing an innovative therapeutic approach for patients with homologous recombination-deficient cancers.
This milestone reflects our ongoing commitment to advancing groundbreaking therapies and offering new possibilities to patients facing challenging diagnoses.’
We’re grateful for our partnership with MOMA Therapeutics and excited about the potential impact of this innovative therapy for patients.
To learn more about this exciting milestone, read MOMA’s press release.”
Quoting MOMA Therapeutics’s post:
“Today marks a significant milestone for MOMA. We have dosed the first patient in the Phase 1 clinical trial for MOMA-313, a novel, highly potent and selective oral polymerase theta helicase inhibitor. MOMA-313 is being developed for subgroups of prostate cancer, pancreatic cancer and breast cancer.
To add to this exciting news, we are thrilled to share the selection of a development candidate for our second lead program, MOMA-341, an oral, potent and selective covalent Werner helicase inhibitor for the treatment of cancers with microsatellite instability.
The MOMA team has worked hard to bring these two potential best-in-class molecules to the clinic through our proprietary KNOMATIC platform.
Learn more about our MOMA-313, MOMA-341 and our KNOMATIC platform from MOMA CEO, Asit Parikh, M.D., Ph.D., below and read the release.”
Proceed to the video attached to the post.
Source: The START Center for Cancer Research/LinkedIn and MOMA Therapeutics/LinkedIn